source
- Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for VertexSionna Therapeutics has axed a cystic fibrosis add-on program after flunking a phase 2 trial, eliminating a would-be challenger to Vertex Pharmaceuticals’ empire. The biotech plans to “take actions…
- Eli Lilly's $3.8 B acquisition of AtaiBeckley signals growing confidence in psychedelics for depressionPsychedelics are being touted as a potential solution for patients who still struggle to find lasting relief from existing FDA‑approved psychiatric medicines. The article notes that many individual…